Women With Stress Urinary Incontinence
Conditions
Brief summary
We will get the impact of duloxetine versus imipramine on therapeutic efficacy in women with SUI.
Detailed description
Background/Purpose: Pharmacologic treatments for female stress urinary incontinence (SUI) include duloxetine and imipramine. Duloxetine and Imipramine has been reported to have clinical significant therapeutic efficacy on female SUI and overactive bladder syndrome. However, there was no randomized controlled study to compare duloxetine and imipramine for the treatment of female SUI. Patients and Methods: We will perform a prospective randomized controlled study to recruit 90 female SUI patients at the Obstetrics & Gynecology outpatient clinic of Far Eastern Memorial Hospital. All SUI female patients will be asked to complete ICIQ-UI, USS, OABSS, and bladder diary before and after 4 weeks' duloxetine versus imipramine treatment.
Interventions
DRUGduloxetine
Duloxetine 30 mg per day
DRUGImipramine
Imipramine 25 mg per day
Sponsors
Far Eastern Memorial Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
25 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Female patients over 25 years old with stress urinary incontinence. * Patients who are currently not considered for surgical treatment. * Patients who have undergone regular Kegel exercises but have poor results.
Exclusion criteria
* The result of urodynamic examination, if the main cause of urinary incontinence is detrusor overactivity. * Those who are taking or plan to take monoamine oxidase inhibitor (MAOI) inhibitors. * Patients with acute myocardial infarction. * Those who are allergic to duloxetine, imipramine and dibenzazepine tricyclic antidepressants. * Patients with uncontrolled narrow-angle glaucoma. * Pregnant women. * Those who are contraindicated to duloxetine or imipramine. * Patients with suicidal ideation and behavior.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Improvement of stress urinary incontinence | 4 weeks | Urinary Incontinence Questionnaire (by ICIQ-UI short form) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Improvement of urgency symptoms | 4 weeks | Urgency severity scale |
| Improvement of overactive bladder symptoms | 4 weeks | Overactive bladder symptom score |
Countries
Taiwan
Contacts
Primary ContactSheng-Mou Hsiao, MD
Outcome results
None listed